The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 23, 2021

Filed:

Sep. 12, 2017
Applicant:

Ambrx, Inc., La Jolla, CA (US);

Inventors:

Zhenwei Miao, San Diego, CA (US);

Kyle Atkinson, Golden, CO (US);

Sandra Biroc, Alameda, CA (US);

Timothy Buss, Carlsbad, CA (US);

Melissa Neal, Vista, CA (US);

Vadim Kraynov, San Diego, CA (US);

Robin Marsden, San Diego, CA (US);

Jason Pinkstaff, San Rafael, CA (US);

Lillian Skidmore, San Diego, CA (US);

Ying Sun, San Diego, CA (US);

Agnieszka Szydlik, San Francisco, CA (US);

Delia Ianina Lopez De Valenta, Poway, CA (US);

Assignee:

Ambrx, Inc., La Jolla, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 5/00 (2006.01); C07K 5/103 (2006.01); C07D 207/08 (2006.01); C07D 401/12 (2006.01); C07D 417/12 (2006.01); C07K 5/02 (2006.01); A61K 47/68 (2017.01); A61K 38/07 (2006.01); C07K 5/062 (2006.01);
U.S. Cl.
CPC ...
C07K 5/101 (2013.01); A61K 38/07 (2013.01); A61K 47/6803 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6855 (2017.08); A61K 47/6861 (2017.08); C07D 207/08 (2013.01); C07D 401/12 (2013.01); C07D 417/12 (2013.01); C07K 5/0205 (2013.01); C07K 5/06043 (2013.01);
Abstract

Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.


Find Patent Forward Citations

Loading…